About Us

Offices | Customers | Scientific Advisory Board

Rosetta Biosoftware develops informatics solutions and provides services that enable research organizations to efficiently and effectively conduct life-saving discoveries and develop drugs. Our mission is to be the premier provider of scalable software solutions to empower research that improves the quality of human life.

We provide value to discovery and development efforts by offering customizable informatics solutions and services that are adaptable to your needs. We are a customer-driven organization with the scientific expertise to effectively complement your internal informatics groups or serve as an informatics resource.

Offices

Rosetta Biosoftware has offices in London, Seattle and Tokyo. Our headquarters are located in the South Lake Union neighborhood in Seattle at 401 Terry Avenue North, Seattle, Washington, 98109. [map]

top of the page

Customers

We are privileged to work with some of the world's leading life sciences corporations and academic institutions. Below is a partial list of Rosetta Biosoftware's customers:

• Abbott Laboratories
• Asahi Breweries
• BioASP
• Biogen IDEC
• Bristol-Myers Squibb
• California Institute of Technology
• Eisai Company, Limited
• Genentech
• Harvard University
• Japan Tobacco
• Max Planck Institute
• Merck & Co., Inc.
• Merck Serono
• Monsanto
• National Institute of Environmental Health Sciences (NIEHS)
• National Institute of Radiological Sciences (NIRS Japan)
• National Oceanic and Atmospheric Administration (NOAA)
• Pfizer
• RIKEN
• Sanofi-Aventis
• Schering-Plough
• University of California Los Angeles
• United States Environmental Protection Agency (EPA)
• University of Tokyo
• University of Washington
• Washington State University
• The Wistar Institute

top of the page

Scientific Advisory Board

The Rosetta Biosoftware Scientific Advisory Board provides guidance for the future development and commercialization of products in the area of proteomics. By leveraging expert knowledge, we can create superior products and continue to support advancements in the proteomics field.

Members of the Rosetta Scientific Advisory Board

Dr. Ruedi Aebersold is one of the pioneers in the field of proteomics. He is known for developing a series of methods that have found wide application in analytical protein chemistry and proteomics like a new class of reagents termed Isotope Coded Affinity Tag (ICAT) reagents used in quantitative mass spectrometry. Dr. Aebersold and his team of researchers use the protein profiles determined by the method to differentiate cells in different states, such as noncancerous versus cancerous cells, and to systematically study how cells respond to external stimuli. These "snapshot" profiles indicate which cells contain abnormal levels of certain proteins. This is expected to lead to new diagnostic markers for disease and to a more complete understanding of the biochemical processes that control and constitute cell physiology.

Dr. Aebersold serves on the Scientific Advisory Committees of a number of academic and private sector research organizations and is a member of several editorial boards in the fields of protein science, genomics, and proteomics. He is a native of Switzerland and earned his Ph.D. in Cellular Biology at the Biocenter of the University of Basel in 1983. Since that time, he served on the faculties of the Universities of Washington and British Columbia, until 2000, when he co-founded the Institute for Systems Biology in Seattle. In 2004, he accepted a position as full professor at the Institute for Biotechnology at the Swiss Federal Institute of Technology (ETH) in Zurich, where in January 2005, his research group became the first integral part of the newly founded Institute for Molecular Systems Biology.

Dr. Ronald C. Hendrickson, is the director of Proteomics in the department of Molecular Profiling at Merck Research Laboratories in Rahway, New Jersey, USA. Currently, he is applying state-of-the-art mass spectrometry techniques to rapidly identify and quantify changes in proteins related to disease or therapeutic agents. Prior to joining Merck, Dr. Hendrickson served as a Vice President for MDS Proteomics (Protana), a leading proteomics company founded on emerging informatics tools and nano-electrospray technology developed the EMBL. He also served as Chairman of the MDS Proteomics-Harvard Partners Joint Steering Committee. This strategic alliance was established to combine the collective expertise of clinical investigators and state of the art proteomics to speed the discovery, development and commercialization of innovative healthcare products.

Dr. Hendrickson joined Protana in Odense Denmark to work with Matthias Mann and Ole Vorm At Protana, his research efforts expanded into large-scale protein-protein interaction studies using yeast as a model organism. Prior to joining Protana, Dr. Hendrickson was employed by Corixa Corporation in Seattle, Washington, USA. His research at Corixa involved identifying tumor antigens and serological markers for Breast cancer and Tuberculosis.

Dr. Hendrickson received his B.S. in Chemistry from the University of Washington and his Ph.D. in Chemistry from the University of Virginia. Under the guidance of Professor Donald F. Hunt, Dr. Hendrickson developed and applied high-sensitivity mass spectrometry to biological research. His research efforts included identification of phosphorylation events involved in signal transduction pathways, MHC restricted peptide antigens recognized by cytotoxic T lymphocytes, and the first T cell recognized tumor antigen that results from post translational modification. His graduate research earned him the Sigma Xi Annual Award for the Outstanding Graduate Research in Biology at the University of Virginia.

Dr. Yoshiya Oda developed a widely used metabolic labeling method for quantitative proteomics, which is featured in the most frequently cited article from the Proceedings of the National Academy of Sciences-Chemistry journal. Dr. Oda is currently a Senior Scientist at Eisai Co., Ltd. Laboratory of Seeds Finding Technology and a visiting Associate Professor at Metabolome Laboratory, Department of Biochemistry and Molecular Biology, Graduate School of Medicine, at the University of Tokyo. He has published numerous papers in the field of proteomics. His research has won awards from the Society for Chromatographic Sciences, the Mass Spectrometry Society of Japan and the Pharmaceutical Society of Japan.

Dr. Oda, a native of Japan, earned his Pharmacy Ph.D. at Kyoto University in 1993. He has served on the faculties at Kyoto University Graduate School, Medical Institute of Bioregulation in Kyushu University and the Graduate School of Medicine at the University of Tokyo.

top of the page